ArticleTherapeutic advances in drug safety2025

A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System.

Jiayan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.